Using proteolysis-targeting chimera technology to reduce navitoclax platelet toxicity and improve its senolytic activity
Open Access
- 24 April 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Nature Communications
- Vol. 11 (1), 1-14
- https://doi.org/10.1038/s41467-020-15838-0
Abstract
Small molecules that selectively kill senescent cells (SCs), termed senolytics, have the potential to prevent and treat various age-related diseases and extend healthspan. The use of Bcl-xl inhibitors as senolytics is largely limited by their on-target and dose-limiting platelet toxicity. Here, we report the use of proteolysis-targeting chimera (PROTAC) technology to reduce the platelet toxicity of navitoclax (also known as ABT263), a Bcl-2 and Bcl-xl dual inhibitor, by converting it into PZ15227 (PZ), a Bcl-xl PROTAC, which targets Bcl-xl to the cereblon (CRBN) E3 ligase for degradation. Compared to ABT263, PZ is less toxic to platelets, but equally or slightly more potent against SCs because CRBN is poorly expressed in platelets. PZ effectively clears SCs and rejuvenates tissue stem and progenitor cells in naturally aged mice without causing severe thrombocytopenia. With further improvement, Bcl-xl PROTACs have the potential to become safer and more potent senolytic agents than Bcl-xl inhibitors.Funding Information
- NIH
This publication has 51 references indexed in Scilit:
- Oxidation resistance 1 is a novel senolytic targetAging Cell, 2018
- Senotherapeutics for healthy ageingNature Reviews Drug Discovery, 2018
- Senescent cells: an emerging target for diseases of ageingNature Reviews Drug Discovery, 2017
- Cellular Senescence: A Translational PerspectiveEBioMedicine, 2017
- Identification of a novel senolytic agent, navitoclax, targeting the Bcl‐2 family of anti‐apoptotic factorsAging Cell, 2016
- Small‐Molecule PROTACS: New Approaches to Protein DegradationAngewandte Chemie, 2016
- Selective Small Molecule Induced Degradation of the BET Bromodomain Protein BRD4ACS Chemical Biology, 2015
- Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4Cell Chemical Biology, 2015
- ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing plateletsNature Medicine, 2013
- The Senescence-Associated Secretory Phenotype: The Dark Side of Tumor SuppressionAnnual review of pathology, 2010